EDIT
Price
$7.81
Change
-$0.12 (-1.51%)
Updated
Feb 23, 6:59 PM EST
3 days until earnings call
HRTX
Price
$2.60
Change
-$0.02 (-0.76%)
Updated
Feb 23, 6:59 PM EST
2 days until earnings call
Ad is loading...

EDIT vs HRTX ᐉ Comparison: Which is Better to Invest?

Header iconEDIT vs HRTX Comparison
Open Charts EDIT vs HRTXBanner chart's image
Editas Medicine
Price$7.81
Change-$0.12 (-1.51%)
Volume$602.9K
CapitalizationN/A
Heron Therapeutics
Price$2.60
Change-$0.02 (-0.76%)
Volume$896.56K
CapitalizationN/A
View a ticker or compare two or three
EDIT vs HRTX Comparison Chart

Loading...

EDITDaily Signal changed days agoGain/Loss if shorted
 
Show more...
HRTXDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
EDIT vs. HRTX commentary
Feb 25, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EDIT is a StrongSell and HRTX is a Sell.

COMPARISON
Comparison
Feb 25, 2024
Stock price -- (EDIT: $7.81 vs. HRTX: $2.60)
Brand notoriety: EDIT and HRTX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: EDIT: 70% vs. HRTX: 45%
Market capitalization -- EDIT: $637.87M vs. HRTX: $390.19M
EDIT [@Biotechnology] is valued at $637.87M. HRTX’s [@Biotechnology] market capitalization is $390.19M. The market cap for tickers in the [@Biotechnology] industry ranges from $550.21B to $0. The average market capitalization across the [@Biotechnology] industry is $2.58B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EDIT’s FA Score shows that 0 FA rating(s) are green whileHRTX’s FA Score has 0 green FA rating(s).

  • EDIT’s FA Score: 0 green, 5 red.
  • HRTX’s FA Score: 0 green, 5 red.
According to our system of comparison, both EDIT and HRTX are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EDIT’s TA Score shows that 4 TA indicator(s) are bullish while HRTX’s TA Score has 3 bullish TA indicator(s).

  • EDIT’s TA Score: 4 bullish, 4 bearish.
  • HRTX’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, EDIT is a better buy in the short-term than HRTX.

Price Growth

EDIT (@Biotechnology) experienced а -4.17% price change this week, while HRTX (@Biotechnology) price change was -9.41% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.03%. For the same industry, the average monthly price growth was +18.51%, and the average quarterly price growth was +38.88%.

Reported Earning Dates

EDIT is expected to report earnings on May 01, 2024.

HRTX is expected to report earnings on May 09, 2024.

Industries' Descriptions

@Biotechnology (+2.03% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for EDIT with price predictions.
OPEN
A.I.dvisor published
a Summary for HRTX with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
EDIT($638M) has a higher market cap than HRTX($390M). HRTX YTD gains are higher at: 52.941 vs. EDIT (-22.902). HRTX has higher annual earnings (EBITDA): -122.67M vs. EDIT (-202.49M). EDIT has more cash in the bank: 350M vs. HRTX (77.4M). EDIT has less debt than HRTX: EDIT (34.6M) vs HRTX (180M). HRTX has higher revenues than EDIT: HRTX (123M) vs EDIT (24.6M).
EDITHRTXEDIT / HRTX
Capitalization638M390M164%
EBITDA-202.49M-122.67M165%
Gain YTD-22.90252.941-43%
P/E RatioN/AN/A-
Revenue24.6M123M20%
Total Cash350M77.4M452%
Total Debt34.6M180M19%
FUNDAMENTALS RATINGS
EDIT vs HRTX: Fundamental Ratings
EDIT
HRTX
OUTLOOK RATING
1..100
1690
VALUATION
overvalued / fair valued / undervalued
1..100
34
Fair valued
68
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
97100
PRICE GROWTH RATING
1..100
8137
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EDIT's Valuation (34) in the Biotechnology industry is somewhat better than the same rating for HRTX (68). This means that EDIT’s stock grew somewhat faster than HRTX’s over the last 12 months.

EDIT's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as HRTX (100). This means that EDIT’s stock grew similarly to HRTX’s over the last 12 months.

EDIT's SMR Rating (97) in the Biotechnology industry is in the same range as HRTX (100). This means that EDIT’s stock grew similarly to HRTX’s over the last 12 months.

HRTX's Price Growth Rating (37) in the Biotechnology industry is somewhat better than the same rating for EDIT (81). This means that HRTX’s stock grew somewhat faster than EDIT’s over the last 12 months.

HRTX's P/E Growth Rating (100) in the Biotechnology industry is in the same range as EDIT (100). This means that HRTX’s stock grew similarly to EDIT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EDITHRTX
RSI
ODDS (%)
Bullish Trend 3 days ago
90%
Bearish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
80%
Bearish Trend 3 days ago
85%
Momentum
ODDS (%)
Bullish Trend 3 days ago
79%
Bullish Trend 3 days ago
79%
MACD
ODDS (%)
Bullish Trend 3 days ago
77%
Bearish Trend 3 days ago
85%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 3 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
87%
Bullish Trend 3 days ago
76%
Advances
ODDS (%)
Bullish Trend 11 days ago
77%
Bullish Trend 11 days ago
79%
Declines
ODDS (%)
Bearish Trend 3 days ago
86%
Bearish Trend 3 days ago
83%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
79%
Bearish Trend 3 days ago
83%
Aroon
ODDS (%)
Bearish Trend 3 days ago
87%
Bullish Trend 3 days ago
80%
View a ticker or compare two or three
Ad is loading...
EDITDaily Signal changed days agoGain/Loss if shorted
 
Show more...
HRTXDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RSCKX4.890.02
+0.41%
Victory RS Small Cap Equity R
HDVRX11.760.02
+0.17%
Hartford International Equity R3
SWISX23.180.04
+0.17%
Schwab International Index
MDVZX8.310.01
+0.12%
Manning & Napier Disciplined Value Z
BDOAX9.750.01
+0.10%
iShares MSCI Total Intl Idx Inv A

EDIT and

Correlation & Price change

A.I.dvisor indicates that over the last year, EDIT has been closely correlated with NTLA. These tickers have moved in lockstep 70% of the time. This A.I.-generated data suggests there is a high statistical probability that if EDIT jumps, then NTLA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EDIT
1D Price
Change %
EDIT100%
-1.51%
NTLA - EDIT
70%
Closely correlated
-3.97%
BEAM - EDIT
68%
Closely correlated
+1.34%
DNLI - EDIT
58%
Loosely correlated
+0.59%
VCYT - EDIT
56%
Loosely correlated
-8.87%
NRIX - EDIT
54%
Loosely correlated
-3.32%
More

HRTX and

Correlation & Price change

A.I.dvisor indicates that over the last year, HRTX has been loosely correlated with MDGL. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if HRTX jumps, then MDGL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HRTX
1D Price
Change %
HRTX100%
-0.76%
MDGL - HRTX
49%
Loosely correlated
-4.82%
AMRN - HRTX
44%
Loosely correlated
+0.85%
ORMP - HRTX
43%
Loosely correlated
+4.85%
CRSP - HRTX
41%
Loosely correlated
-2.55%
NTLA - HRTX
39%
Loosely correlated
-3.97%
More